Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Phosphoinositide 3-kinase (PI3K) inhibitors

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Phosphoinositide 3-kinase (PI3K) inhibitors are a class of drugs that target the Rapamycin (PI3K-Akt-mTOR) pathway, which is crucial for regulating cell growth, proliferation, and survival. This pathway is often dysregulated in various cancers, making PI3K inhibitors a significant focus in cancer therapy research.

Phosphoinositide 3-kinase (PI3K) inhibitors can be categorized based on their specificity:

Isoform-specific inhibitors: These target specific PI3K isoforms such as Phosphoinositide 3-Kinase (PI3K) isoform alfa, Phosphoinositide 3-Kinase (PI3K) isoform beta, [Phosphoinositide 3-Kinase (PI3K) …

References (Sources)

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
Hanker et al. 2019 Cancer Discovery 9: 482
Review
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Damodaran et al. 2022 J Clin Oncol 40: 1552-1561
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020)
Sabbah et al. 2021 Expert Opin Ther Pat. 31(10): 877-892
Review
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
Juvekar et al. 2016 Proc Natl Acad Sci USA 113(30): E4338-47
PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
Zeid & Yazbeck 2023 Blood Lymphat Cancer 13: 1-12
Review
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3IVAkt/mTOR Pathway
Morgan et al. 2009
The present and future of PI3K inhibitors for cancer therapy
Castel et al. 2021 Nat Cancer 2(6): 587-597

AI Chat

7/1/2026

Chat with our artificial intelligence:

Links

Phosphoinositide 3-kinase inhibitor - Wikipedia